Nuevocor

Biotechnology ResearchCentral Region, Singapore11-50 Employees

Nuevocor is a small biotechnology company focused on developing genetic medicines for untreatable genetic cardiomyopathies. Headquartered in Singapore's Central Region and with offices in the United States, the company aims to translate mechanobiology-based insights into therapies. Operating at the clinical-stage, it pursues treatment approaches for conditions such as LMNA-associated dilated cardiomyopathy.

Its focus encompasses cardiomyopathies driven by aberrant mechanobiology, including LMNA-related forms. In April 2026, Nuevocor announced the appointment of Monica Shah as Chief Medical Officer to guide global clinical development as it prepares to initiate a first-in-human study of NVC-001.

Sign up for free to view info

Email Format Employee directory